Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC

Inference and analysis of cell-cell communication using CellChat

(2021) Suoqin Jin et al.   Nature Communications

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

(2021) Karthik Dhatchinamoorthy et al.   Frontiers in Immunology

Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?

(2021) Elissar Moujaess et al.   Immunotherapy

Molecular determinants of response to PD-L1 blockade across tumor types

(2021) Romain Banchereau et al.   Nature Communications

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

(2021) Ye Wang et al.   Frontiers in Oncology

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future

(2020) Eric S Christenson et al.   LANCET ONCOLOGY

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

(2020) Jia-qiao Fan et al.   Molecular Cancer

Identification of Potential Biomarkers Associated with Basal Cell Carcinoma

(2020) Yong Liu et al.   Biomed Research International

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

(2020) Luisa Chocarro de Erauso et al.   Frontiers in Pharmacology

Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity

(2020) Sandra Grund‐Gröschke et al.   Molecular Oncology

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies

(2020) Gabriela Reyes-Castellanos et al.   Biomedicines

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

(2020) D.J. Renouf et al.   ANNALS OF ONCOLOGY

The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data

(2020) Axel Bengtsson et al.   Scientific Reports

Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers

(2020) Emmanuel Dollinger et al.   Cancers

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

(2020) Rilan Bai et al.   Biomarker Research

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

(2020) Jin-Yu Sun et al.   Biomarker Research

Comprehensive Integration of Single-Cell Data

(2019) Tim Stuart et al.   CELL

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

(2019) Vivek Verma et al.   NATURE IMMUNOLOGY

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages

(2019) Marco Orecchioni et al.   Frontiers in Immunology

T Cell Dysfunction in Cancer Immunity and Immunotherapy

(2019) Anliang Xia et al.   Frontiers in Immunology

Diagnostic and prognostic implications of ribosomal protein transcript expression patterns in human cancers

(2018) James M. Dolezal et al.   BMC CANCER

Heterogeneous relationships of squamous and basal cell carcinomas of the skin with smoking: the UK Million Women Study and meta-analysis of prospective studies

(2018) Kirstin Pirie et al.   BRITISH JOURNAL OF CANCER

Inhibitors of the PD-1 Pathway in Tumor Therapy

(2018) Martin W. LaFleur et al.   JOURNAL OF IMMUNOLOGY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

(2018) Scott J. Rodig et al.   Science Translational Medicine

Identification of potential target genes in pancreatic ductal adenocarcinoma by bioinformatics analysis

(2018) Yuchen Tang et al.   Oncology Letters

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment

(2018) Etienne D. Foucher et al.   Frontiers in Immunology

The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

(2018) Lumir Kunovsky et al.   Canadian Journal of Gastroenterology and Hepatology

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Understanding the Molecular Genetics of Basal Cell Carcinoma

(2017) Cristina Pellegrini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

(2017) Michal Šmahel   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor and Intertumor Heterogeneity in Melanoma

(2017) Tomasz M. Grzywa et al.   Translational Oncology

Heat Shock Proteins and Cancer

(2017) Jianming Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Combination immunotherapy: a road map

(2017) Patrick A. Ott et al.   Journal for ImmunoTherapy of Cancer

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

(2016) Ximena Bonilla et al.   NATURE GENETICS

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

The role of S100 proteins and their receptor RAGE in pancreatic cancer

(2015) Estelle Leclerc et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Recent progress in pancreatic cancer

(2013) Christopher L. Wolfgang et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combination immunotherapy approaches

(2012) C. G. Drake   ANNALS OF ONCOLOGY

Trefoil Factor 1 Stimulates Both Pancreatic Cancer and Stellate Cells and Increases Metastasis

(2011) Thiruvengadam Arumugam et al.   PANCREAS

Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas

(2010) A. Walter et al.   CLINICAL CANCER RESEARCH

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY